*Patients were randomized 1:1 to receive ERLEADA® 240 mg orally once daily (n=525) or placebo orally once daily (n=527).1,3

†Patients receiving ERLEADA® should also receive a gonadotropin-releasing hormone (GnRH) analog concurrently or should have had bilateral orchiectomy.1

THOUGHT LEADER SERIES: REAL-WORLD EVIDENCE IN THE TREATMENT OF mCSPC

Hear the experts share their perspective on treating advanced prostate cancer.

Head-to-head real-world evidence: ERLEADA® vs enzalutamide

Dr. Joelle Hamilton reviews a statistically powered, real-world analysis comparing ERLEADA® vs enzalutamide.

Joelle Hamilton, MD
Medical Oncologist, Division of Hematology and Oncology at University of Alabama, Birmingham

Head-to-head real-world evidence: ERLEADA® vs abiraterone acetate

Dr. Gordon A. Brown reviews a statistically powered, real-world analysis comparing ERLEADA® vs abiraterone acetate.

Gordon A. Brown, DO, FACOS
Associate Professor and Program Director, Urologic Surgery at Rowan University School of Medicine Program Director, Center for Advanced Therapeutics New Jersey Urology

ADT, androgen deprivation therapy; CI, confidence interval; GnRH, gonadotropin-releasing hormone; HR, hazard ratio; mCSPC, metastatic castration-sensitive prostate cancer; NE, not estimable; NR, not reached; OS, overall survival.

REFERENCES:

  1. ERLEADA® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.
  2. Chi KN, Chowdhury S, Bjartell A, et al. Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study. J Clin Oncol. 2021;39(20):2294-2303.
  3. Chi KN, Agarwal N, Bjartell A, et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med. 2019;381(1):13-24.